Quantitative Investment Management LLC Takes Position in Zoetis Inc. $ZTS

Quantitative Investment Management LLC acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 45,119 shares of the company’s stock, valued at approximately $3,242,000.

Other large investors also recently bought and sold shares of the company. Moore Capital Management LP purchased a new position in Zoetis in the 2nd quarter worth about $14,570,000. Sigma Planning Corp grew its stake in shares of Zoetis by 32.7% in the second quarter. Sigma Planning Corp now owns 12,694 shares of the company’s stock worth $912,000 after acquiring an additional 3,131 shares during the period. Two Sigma Securities LLC bought a new stake in shares of Zoetis in the second quarter worth approximately $3,049,000. Private Harbour Investment Management & Counsel LLC raised its holdings in shares of Zoetis by 1.6% during the second quarter. Private Harbour Investment Management & Counsel LLC now owns 12,106 shares of the company’s stock valued at $870,000 after purchasing an additional 193 shares during the last quarter. Finally, Flputnam Investment Management Co. raised its holdings in shares of Zoetis by 1,595.7% during the second quarter. Flputnam Investment Management Co. now owns 30,218 shares of the company’s stock valued at $2,171,000 after purchasing an additional 28,436 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ZTS shares. HSBC dropped their target price on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Piper Sandler lowered their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. BNP Paribas Exane reduced their price target on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Citigroup lowered their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Finally, Argus restated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $107.43.

Zoetis Price Performance

Shares of Zoetis stock opened at $77.45 on Monday. The stock has a market cap of $32.00 billion, a P/E ratio of 12.76, a P/E/G ratio of 1.80 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The stock’s fifty day moving average is $75.57 and its 200 day moving average is $95.40. Zoetis Inc. has a one year low of $71.00 and a one year high of $156.49.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current year.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.